scholarly journals Microarray-based detection and expression analysis of extracellular matrix proteins in drug-resistant ovarian cancer cell lines

2014 ◽  
Vol 32 (5) ◽  
pp. 1981-1990 ◽  
Author(s):  
RADOSŁAW JANUCHOWSKI ◽  
PIOTR ZAWIERUCHA ◽  
MARCIN RUCIŃSKI ◽  
MACIEJ ZABEL
Keyword(s):  
Ovarian Cancer ◽  
Extracellular Matrix ◽  
Cell Lines ◽  
Cancer Cell ◽  
Expression Analysis ◽  
Ovarian Cancer Cell ◽  
Extracellular Matrix Proteins ◽  
Matrix Proteins ◽  
Drug Resistant ◽  
Ovarian Cancer Cell Lines

Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines

2013 ◽  
Vol 67 (3) ◽  
pp. 240-245 ◽  
Author(s):  
Radosław Januchowski ◽  
Piotr Zawierucha ◽  
Małgorzata Andrzejewska ◽  
Marcin Ruciński ◽  
Maciej Zabel
Keyword(s):  
Ovarian Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Expression Analysis ◽  
Ovarian Cancer Cell ◽  
Cancer Cell Lines ◽  
Drug Resistant ◽  
Slc Transporters ◽  
Ovarian Cancer Cell Lines

scholarly journals Microarray-based detection and expression analysis of new genes associated with drug resistance in ovarian cancer cell lines

Oncotarget ◽  
2017 ◽  
Vol 8 (30) ◽  
pp. 49944-49958 ◽  
Author(s):  
Radosław Januchowski ◽  
Karolina Sterzyńska ◽  
Piotr Zawierucha ◽  
Marcin Ruciński ◽  
Monika Świerczewska ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Drug Resistance ◽  
Cell Lines ◽  
Cancer Cell ◽  
Expression Analysis ◽  
Ovarian Cancer Cell ◽  
Cancer Cell Lines ◽  
New Genes ◽  
Ovarian Cancer Cell Lines

scholarly journals Analysis of MDR genes expression and cross-resistance in eight drug resistant ovarian cancer cell lines

2016 ◽  
Vol 9 (1) ◽  
Author(s):  
Radosław Januchowski ◽  
Karolina Sterzyńska ◽  
Katarzyna Zaorska ◽  
Patrycja Sosińska ◽  
Andrzej Klejewski ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Ovarian Cancer Cell ◽  
Cancer Cell Lines ◽  
Cross Resistance ◽  
Drug Resistant ◽  
Ovarian Cancer Cell Lines ◽  
Genes Expression ◽  
Mdr Genes

scholarly journals Expression of microRNA-30a-5p in drug-resistant and drug-sensitive ovarian cancer cell lines

2016 ◽  
Vol 12 (3) ◽  
pp. 2065-2070 ◽  
Author(s):  
Jin Liu ◽  
Xiaohua Wu ◽  
Hongmei Liu ◽  
Yijuan Liang ◽  
Xinping Gao ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cell Lines ◽  
Cancer Cell ◽  
Ovarian Cancer Cell ◽  
Cancer Cell Lines ◽  
Drug Resistant ◽  
Ovarian Cancer Cell Lines

scholarly journals Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models

2021 ◽  
Vol 40 (1) ◽  
Author(s):  
Camilla Coulson-Gilmer ◽  
Robert D. Morgan ◽  
Louisa Nelson ◽  
Bethany M. Barnes ◽  
Anthony Tighe ◽  
...  
Keyword(s):  
Gene Expression ◽  
Ovarian Cancer ◽  
Dna Replication ◽  
Cell Lines ◽  
Cancer Cell ◽  
Ovarian Cancer Cell ◽  
Drug Resistant ◽  
Resistant Disease ◽  
Ovarian Cancer Cell Lines ◽  
Cancer Models

Abstract Background Patients with ovarian cancer often present at advanced stage and, following initial treatment success, develop recurrent drug-resistant disease. PARP inhibitors (PARPi) are yielding unprecedented survival benefits for women with BRCA-deficient disease. However, options remain limited for disease that is platinum-resistant and/or has inherent or acquired PARPi-resistance. PARG, the PAR glycohydrolase that counterbalances PARP activity, is an emerging target with potential to selectively kill tumour cells harbouring oncogene-induced DNA replication and metabolic vulnerabilities. Clinical development of PARG inhibitors (PARGi) will however require predictive biomarkers, in turn requiring an understanding of their mode of action. Furthermore, differential sensitivity to PARPi is key for expanding treatment options available for patients. Methods A panel of 10 ovarian cancer cell lines and a living biobank of patient-derived ovarian cancer models (OCMs) were screened for PARGi-sensitivity using short- and long-term growth assays. PARGi-sensitivity was characterized using established markers for DNA replication stress, namely replication fibre asymmetry, RPA foci, KAP1 and Chk1 phosphorylation, and pan-nuclear γH2AX, indicating DNA replication catastrophe. Finally, gene expression in sensitive and resistant cells was also examined using NanoString or RNAseq. Results PARGi sensitivity was identified in both ovarian cancer cell lines and patient-derived OCMs, with sensitivity accompanied by markers of persistent replication stress, and a pre-mitotic cell cycle block. Moreover, DNA replication genes are down-regulated in PARGi-sensitive cell lines consistent with an inherent DNA replication vulnerability. However, DNA replication gene expression did not predict PARGi-sensitivity in OCMs. The subset of patient-derived OCMs that are sensitive to single-agent PARG inhibition, includes models that are PARPi- and/or platinum-resistant, indicating that PARG inhibitors may represent an alternative treatment strategy for women with otherwise limited therapeutic options. Conclusions We discover that a subset of ovarian cancers are intrinsically sensitive to pharmacological PARG blockade, including drug-resistant disease, underpinned by a common mechanism of replication catastrophe. We explore the use of a transcript-based biomarker, and provide insight into the design of future clinical trials of PARGi in patients with ovarian cancer. However, our results highlight the complexity of developing a predictive biomarker for PARGi sensitivity.

Sign in / Sign up

Export Citation Format

Share Document